| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 08/16/2006 | CN1819837A TAMANDARIN analogs and fragments thereof and methods of making and using |
| 08/16/2006 | CN1819822A Compositions containing substituted quinolines and substituted diphenyl sulfones and methods of use |
| 08/16/2006 | CN1819821A Modified-release tablet of bupropion hydrochloride |
| 08/16/2006 | CN1817882A Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 08/16/2006 | CN1817349A Nucleoside analogues with carboxamidine-modified monocyclic base |
| 08/15/2006 | US7091364 Introducing in a reactor a5-amino-3-(carboxyalkyl)-4-cyano-2-thiophenecarboxylic acid, potassium carbonate and a quaternaryammonium salt as catalyst acetone solvent and methyl bromo acetate, heating and cooling |
| 08/15/2006 | US7091310 Chemokine analogs for the treatment of human disease |
| 08/15/2006 | US7091239 DNA polymerase inhibitors, mikanolide and dihydromikanolide |
| 08/15/2006 | US7091235 substituted with p-chlorobenzene and a pyrrolethoxybenzene; antitumor |
| 08/15/2006 | US7091195 Derived from plants; for preventing or inhibiting tumor growth |
| 08/15/2006 | US7089934 Delivery of oral drugs |
| 08/10/2006 | WO2005055956A3 Method for improving insulin sensitivity by administering an inhibitor of antitrypsin |
| 08/10/2006 | WO2005041897A3 Reconstitutable microsphere compositions useful as ultrasonic contrast agents |
| 08/10/2006 | WO2005041856A3 Use of 2-thia-dibenzo[e, h]azulenes for the treatment and prevention of central nervous system diseases and disorders |
| 08/10/2006 | WO2005023189A3 Method of cox-2 selective inhibitor and nitric oxide-donating agent |
| 08/10/2006 | WO2004105694A3 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| 08/10/2006 | WO2004071467A3 Production of very long chain polyunsaturated fatty acids in oilseed plants |
| 08/10/2006 | US20060178396 e.g. (3-endo)-3-(2-Hydroxy-2,2-di-2-thienylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; muscle relaxants, respiratory system disorders; asthma, emphysema, bronchitis, chronic obstructive lung disease, chronic bronchitis, chronic respiratory obstruction, pulmonary fibrosis, pulmonary fibrosis |
| 08/10/2006 | US20060178384 2-(2,6-dimethoxy-phenylamino)-9-methoxy-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one; 3-bromo-N-[3-(9-methoxy-4-oxo-6,7-dihydro-4H-pyrimido[6,1-a]isoquinolin-2-ylamino)-phenyl]-benzamide; kinase inhibitor; neutropenia; cytopenia; anemias |
| 08/10/2006 | US20060178363 Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity |
| 08/10/2006 | US20060178358 e.g. 2-(4-Fluorophenyl)-7-(1-methylpiperidin-4-yl)-3-(2-methylpyrimidin-4-yl)imidazo[1,2-a]-pyridine; protozoal diseases (toxoplasmosis, malaria, African typanosomiasis, Chagas disease, and opportunistic infections) in mammals and birds; controlling coccidiosis in poultry |
| 08/10/2006 | US20060178351 Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents |
| 08/10/2006 | US20060178296 Night-time oral insulin therapy |
| 08/10/2006 | US20060177892 Intracellular formation of peptide conjugates |
| 08/10/2006 | US20060177817 Nucleic acid having a sequence that is codon-optimized for high level expression in a yeast cell; proteins produced provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity |
| 08/10/2006 | US20060177530 Method of treating diabetes type II |
| 08/10/2006 | US20060177497 Gellan gum based oral controlled release dosage forms-a novel platform technology for gastric retention |
| 08/10/2006 | US20060177496 Pharmaceutical formulations |
| 08/10/2006 | US20060177462 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 08/10/2006 | US20060177455 Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
| 08/10/2006 | US20060177418 Using bioactive compounds to induce or accelerate healing of damaged skin |
| 08/09/2006 | EP1688418A2 Chemokine receptor antagonists and methods of use thereof |
| 08/09/2006 | EP1687632A2 Plks as modifiers of the beta catenin pathway and methods of use |
| 08/09/2006 | EP1687447A2 Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke |
| 08/09/2006 | EP1687432A2 Compositions and methods for synergistic induction of antitumor immunity |
| 08/09/2006 | EP1687423A2 Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases |
| 08/09/2006 | EP1687405A2 Ttbks as modifiers of the beta catenin pathway and methods of use |
| 08/09/2006 | EP1687349A2 Polyamine polymers |
| 08/09/2006 | EP1687322A2 Custom vectors for treating and preventing pancreatic cancer |
| 08/09/2006 | EP1687307A2 Substituted imidazo ring systems and methods |
| 08/09/2006 | EP1687066A2 Methods of modulating immunity |
| 08/09/2006 | EP1687033A2 Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines |
| 08/09/2006 | EP1687004A2 Pyridine compounds |
| 08/09/2006 | EP1686992A2 Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| 08/09/2006 | EP1686987A2 Advanced indolinone based protein kinase inhibitors |
| 08/09/2006 | EP1686982A2 Methods and compositions for the treatment of helicobacter pylori -associated diseases using endoperoxide bridge-containing compounds |
| 08/09/2006 | EP1686976A2 Combination of proton pump inhibitor and sleep aid |
| 08/09/2006 | EP1686967A2 Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
| 08/09/2006 | EP1686960A2 Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same |
| 08/09/2006 | EP1686949A2 Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| 08/09/2006 | EP1686948A2 Methods and compositions for the treatment of b cell lymphomas and other cancers |
| 08/09/2006 | EP1686864A2 Calcium dietary supplement |
| 08/09/2006 | EP1573004A4 Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| 08/09/2006 | EP1372741B1 Morpholino imaging and therapy |
| 08/09/2006 | EP1252889B1 Remedies or preventives for pulmonary insufficiency containing diaminotrifluoromethylpyridine derivatives |
| 08/09/2006 | EP1140828B1 3-azabicyclo¬3.1.0|hexane derivatives as opiate receptors ligands |
| 08/09/2006 | CN1816745A Method for diagnosing and treating cancer |
| 08/09/2006 | CN1816619A Method for purifying virus |
| 08/09/2006 | CN1816544A Immunosuppressant compounds and compositions |
| 08/09/2006 | CN1816530A Opthalmic compositions for treating ocular hypertension |
| 08/09/2006 | CN1816529A Pyrazole-amide compounds useful as kinase inhibitors |
| 08/09/2006 | CN1816349A Compositions and methods for WT1 specific immunotherapy |
| 08/09/2006 | CN1816331A Tumor-targeting drug-loaded particles |
| 08/09/2006 | CN1813753A Low dose entecavir formulation and use |
| 08/09/2006 | CN1268328C Coenzyme q and eicosapentaenoic acid (EPA) |
| 08/09/2006 | CN1268322C Pharmaceutical compositions comprising amlodipine maleate |
| 08/08/2006 | US7087603 Pyrazole compounds useful as protein kinase inhibitors |
| 08/08/2006 | US7087229 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 08/08/2006 | US7087096 at least one monoazo or ethenylene pyridine and aniline dye; intense and slightly selective colors with improved radiation resistance and colorfastness |
| 08/03/2006 | WO2005046620A3 Variable appearance tissue markings |
| 08/03/2006 | WO2005041862A3 Neutralizing antibodies against extracellular hexosaminidase for treatment of arthritis |
| 08/03/2006 | WO2005037225A3 Methods for treating disorders of neuronal deficiency with bone marrow-derived cells |
| 08/03/2006 | WO2005016226A3 Pharmaceutical compositions comprising ccr5 antagonists |
| 08/03/2006 | WO2005009333A3 Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
| 08/03/2006 | WO2005000200A3 Novel kinases |
| 08/03/2006 | WO2004093803A3 Photochemotherapeutic compounds for use in treatment of pin1-associated states |
| 08/03/2006 | US20060173199 Stereoselective Ring Closure olefin Metathesis (RCM) reaction and Enzymatic Resolution (ER) for the production of optically pure synthetic intermediates during an organic synthesis; provides 3,6-dihydro-2H-pyrans |
| 08/03/2006 | US20060173062 Use of selective cyclooxygenase-2 inhibitors for the treatment of endometriosis |
| 08/03/2006 | US20060172988 Azetidine compounds |
| 08/03/2006 | US20060172977 Topical administering an acetylcholine esterases inhibitor |
| 08/03/2006 | US20060172943 Restoring vascular function |
| 08/03/2006 | US20060172020 Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabeties |
| 08/03/2006 | US20060172001 Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
| 08/03/2006 | US20060171961 A lysine-glycine-lysine-glycine-Xaa pentapeptide residue complexed with one or more B-cell or T-cell determinants and targeting molecules; influenza type A vaccinations |
| 08/03/2006 | US20060171922 Helper virus-free herpesvirus amplicon particles and uses thereof |
| 08/03/2006 | US20060171920 derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug |
| 08/02/2006 | EP1686130A1 Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents |
| 08/02/2006 | EP1686113A1 Inhibitors of aspartyl protease |
| 08/02/2006 | EP1685847A1 Beta-amyloid-analogue-T-cell epitop vaccine |
| 08/02/2006 | EP1685252A2 Use of cell lines to produce active therapeutic proteins |
| 08/02/2006 | EP1685129A2 Oxime substituted imidazo ring compounds |
| 08/02/2006 | EP1685114A2 Antibacterial and/or antiprotozoal nitroimidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines. |
| 08/02/2006 | EP1684800A2 In vivo efficacy of ny-eso-1 plus adjuvant |
| 08/02/2006 | EP1684798A2 Recombinant intracellular pathogen immunogenic compositions and methods for use |
| 08/02/2006 | EP1684791A2 Compositions and methods to modulate an immune response to an immunogenic therapeutic agent |
| 08/02/2006 | EP1684790A2 Homogeneous preparations of chimeric proteins |
| 08/02/2006 | EP1684785A2 B cell-targeted toxins for humoral immune response reduction |
| 08/02/2006 | EP1684784A2 Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders |
| 08/02/2006 | EP1684774A2 STIMULATION OF HAIR GROWTH BY i GINKGO BILOBA /i FLAVANOIDS |
| 08/02/2006 | EP1684773A1 Composition for topic use containing an extract of stryphnodendron, its preparation as well as its application |